Across TCGA pan-cancer cohorts, PRAMEF10 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated PRAMEF10 data layer compared with 2 for mutation status.
The strongest signal is observed in cholangiocarcinoma (CHOL), where higher PRAMEF10 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRAMEF10 expression acts as an unfavorable survival marker, although some lineages such as LIHC show a favorable association.
CHOL, COAD, and UVM are the cancer types where PRAMEF10 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.